COVID-19 in 3 patients treated with immune checkpoint inhibitors for advanced melanoma.

Arenbergerova, M; Gkalpakiotis, S; Arenberger, P; Fialova, A; Pasek, M

Arenbergerova, M; Gkalpakiotis, S; Arenberger, P; Fialova, A; Pasek, M.

Afiliación

Arenbergerova M; Department of Dermatovenereology, Third Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital, Prague, Czech Republic.
Gkalpakiotis S; Department of Dermatovenereology, Third Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital, Prague, Czech Republic.
Arenberger P; Department of Dermatovenereology, Third Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital, Prague, Czech Republic.
Fialova A; Department of Dermatovenereology, Third Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital, Prague, Czech Republic.
Pasek M; Department of Dermatovenereology, Third Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital, Prague, Czech Republic.

J Dermatolog Treat ; 33(3): 1782-1783, 2022 05.

Article en En | MEDLINE | ID: mdl-33092421

Asunto(s)

COVID-19; Melanoma; Neoplasias Cutáneas; Humanos; Inhibidores de Puntos de Control Inmunológico/efectos adversos; Melanoma/tratamiento farmacológico; Neoplasias Cutáneas/tratamiento farmacológico

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / COVID-19 / Melanoma Límite: Humans Idioma: En Revista: J Dermatolog Treat Asunto de la revista: DERMATOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: República Checa

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google